Alembic Pharmaceuticals has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for the inspection carried out by them at the company's API-III Facility at Karakhadi from March 17, 2025 to March 21, 2025.
Earlier, the company had successfully completed the USFDA inspection for its API-III Facility located at Karakhadi. This was a scheduled GMP inspection and was successfully completed without any Form 483 observation.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.
